| HOME >> BIOLOGY >> TECHNOLOGY |
, we believe, the holders' individual financial circumstances.
We believe MedCap's argument that debt could be bought at a discount in liquidation is misleading to stockholders because it inflates the value likely available to common stockholders in the liquidation process.
MedCap has utilized third parties references, which are abbreviated and taken out of context, in ways which could easily mislead stockholders.
MedCap has referenced a report issued by Sharon Seiler, Ph.D., the Senior Biotechnology Analyst at Punk Ziegel and Co. In referring to Dr. Seiler's report, MedCap chose to reference only a fraction of a quote from Dr. Seiler's report, thus changing the meaning entirely. The full quotation is as follows (language omitted by MedCap underlined): "Including the $30.06 million ($0.91 per share) in convertible debt and assuming that the Company's South San Francisco plant could be sold for $10m ($0.30 per share), we would value VaxGen at approximately $1.35 per share before any expenses associated with cessation of operations. We find it hard to envision a scenario in which investors would actually have realized $1.35 per VaxGen share in cash."
MedCap also neglects to point out that the report is subtitled: "We endorse the merger and remain cautiously optimistic regarding the vote" and that Dr. Seiler further states: "We think a shareholder vote to reject the merger with Raven would represent a fairly disastrous outcome for VaxGen and would view it as a clear signal to sell VaxGen shares."
ISS Recommendations
The text of ISS' recommendation on the VaxGen-Raven merger proposal is
as follows: "Based on our review of the terms of the transaction, in
particular, the 41.4 percent decline in stock price following the merger
announcement, lack of a strategic rationale with respect to future
synergies, and the possibility of receiving higher liquidation proceed than
the current stock price, we recommend that shareholders vote AG
'/>"/>
| SOURCE VaxGen Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. VaxGen Files 2006 Financial Statements and Provides Cash Update
2. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
3. VaxGen Files First Quarter 2007 Financials
4. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
5. VaxGen Files Last Outstanding Periodic Report With SEC
6. VaxGen Addresses MPM Claims in Letter to Stockholders
7. VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board
8. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
9. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
10. VaxGen to Present at the 10th Annual BIO CEO and Investor Conference
11. VaxGen Reports Financial Update
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |